China fine chemical network - October 25, reporter from the 14th Beijing international biomedicine industry development BBS about 10 billion yuan, three biological medicine item in this city construction. On the same day, the largest domestic pharmaceutical companies -- China enterprise group (hereinafter referred to as "enterprise group") announced its student group and its subordinate lanzhou, wuhan and changchun and so on six big biological products which has confirmed that the whole appears on the market.
Meanwhile, yunnan province 1025 "published" during vigorously develops the biological medicine, strive to achieve the billions scale.
Shanghai and Beijing are brewing issued his biological medicine "1025" planning. Shanghai is the overall objective of the end of 2012, to, make biological pharmacy economic volume 200 billion yuan. Support 100 annual output more than 2 billion yuan of innovative enterprise, make 100 sales more than 100 million yuan, a high content of technology fist product, And the Beijing strive to future three years the biomedicine industry scale from now of less than 400 million yuan increased to 100 billion yuan.
By 2010, yunda China biomedicine industry momentum of development such as emerging of the fire, quite have the fervour of power.
Flame is lit on October 18, the state council on speeding up the cultivating and developing strategic decision of emerging industries. Present will focus on energy conservation, environmental protection, cultivate and develop a new generation of information technology, biological seven new industry, until 2015, strategic emerging industry proportion of GDP to reach 8%.
Biological medicine is the next decade, the sunrise industry has been unquestionable. Chinese medicine transformation of scientific and technological achievements, director of the center RuiGuoZhong forecast, 2013 Chinese medicine market will become the world's third-biggest medicine market, By 2020, China biomedicine industry will reach the scale of 40000 million yuan, more than Japan and Europe to become the world's second largest pharmaceutical market. China in the global biomedicine industry growing status of ascension.
Multiple positive policy is coming out
Relevant expert points out, the 2010-2015 biomedicine industry revitalization planning "are being made in, before the end of the year is expected to come. Meanwhile, a batch of matching policy will around "1025" planning to come on stage, is expected to advance listed.
China biomedicine industry are entering policies benefiting period. According to introducing, "RuiGuoZhong from the macroscopic new medical policies overall implementation, base expanded version, new medicine GMP pharmaceutical production management (standard), biological medicine 863 plan, major new drugs oriented technology, to refining industry special the major infectious disease special", "drug registration management method", "new measures for the administration of medical devices, the Chinese medicine injection of new technology standards etc 689 policies, including throughout the biological medicine policy support, are all expected to come." year These good policy "not only more fierce, and concentrated, will reconstruct Chinese biological pharmacy chains."
China pharmaceutical industry confidence to Shanghai securities ZhongQian, director of the center, said biological medicine "1025" programming will put forward nine key projects, in which the first item is developing biological medicine to promote traditional Chinese medicine industry upgrading and give capital support. "To promote the pharmaceutical industry upgrading industries target, matching policy will soon out."
New GMP pharmaceutical industry and pharmaceutical standards () is now the biggest concern for one of the corresponding policy. China pharmaceutical enterprise management association, said YuMingDe drug quality guarantee system upgrade is the pharmaceutical industry is an important component of the overall upgrade. It is also decided to drug safety effective a foundation. "Revision GMP has passed, walking program, and also is expected to recent calafornia."
ZhongQian tells a reporter, new GMP have three years of transition, exceed the time limit not standard by the enterprise, namely were ordered to rectification or shut-down. "GMP pharmaceutical manufacturing company of the software requirements have boosted, this has been our medical enterprises the soft rib of."
Besides pharmaceutical standards, new drug product standards and the upgrade process. "In this five-year plan, the country will have a series of practical action to promote drug product standards improve. Including Chinese traditional medicine, tcmi, biochemical drugs, including apis and preparations injection impurities control and solvent residual, plus some new inspection items and methods. These are big change, also might release some new modern medicine product standards." YuMingDe said.
At the same time, to improve the innovation ability, the Shanghai securities reporter sole learns, and biological medicine "1025" planning also issued and major new drugs oriented 1025 "special" planning. For a significant innovation medicine development fund support scale will from the eleventh five-year plan period 6.6 billion expanded to 105 billion. The first 300 the winning project is expected to announce also years. Single drug development project support fund scale ranging from 100 to 10 million, technical development platform support from 1,000 to scale is 60 million dollars. These policies will be "the temptation" enterprise to increase development in addition, according to the Shanghai science and technology commission biological medicine place ZhengZhongMin revealed, deputy director of the legislative affairs office of the state council is in the present drug registration management method ", "new measures for the administration of medical devices, and hope it can discuss" scientific research institution between enterprises of the industrialization of the positioning."
High growth, high profit margin of the dual temptation
YuMingDe said the nation "1025" planning to determine the biological medicine, including genetic focusing on the development of drugs, protein drugs, single drug resistance, therapeutic cloning vaccine, small molecules chemical medicines, etc, these policies will actively promote the rapid development of China biological medicine, biological medicine industry exciting.
An adviser pharmaceutical industry GuoFan ritual to reporters researchers pointed out that China biomedicine industry in the future will remain rapid growth. "2009, China biological medicine industry total sales income reached 753 billion yuan, this development speed make it become the most rapidly growing pharmaceutical industry to one area. Meanwhile, biomedicine industry profit rate up to 70% high development speed and profitable growth also make biomedicine industry becomes emerging industry in one of the most remarkable object."
In the policy guidance and profitable, high rate of stimulating, a batch of traditional Chinese medicine companies will also send biological pharmaceutical companies change.
Specializes in production of traditional Chinese medicine intermediates for apis, main products listed pharmaceutical company manager told reporters, the company plans to use 5 to 10 years, thoroughly transform for biological pharmaceutical companies and has on research into huge funds. He revealed. "for refining comparing vaccine r&d investment projects 8,000 yuan, 2 years of RenYuan listed sales; anti-tumor bad factor of single resistance of total investment of the project 1 billion yuan.
Biological medicine investment projects for traditional medicine enterprise has brought tangible and sustainable profit growth. According to health yuan, deputy general manager of zhongshan introduces, at present by biological catalysis in henan jiaozuo way 7aca non-nanoparticlized antibiotics intermediates production has been very successful, the project has become the most important, and fastest growing source of their profits. "We use for soybean, corn fermentation to produce 7aca, free from pollution to the environment, current capacity is expanding."
In the United States nyse successful listing, China's largest high-tech medical equipment company - shenzhen Wallace rui biological medical electronics Co., relevant personage is put forward to the reporter, in the biological electronic medical devices field exists industrial supporting, technical standard loss, and foreign companies extrusion problems. He told reporters can foresee, 10 years biomedicine industry concentration more and more high, for large leading enterprises, government should provide better service, make public research and development platform, in order to improve their competitiveness.
For now, the government department all around has realised biomedicine industry for local economic development, and has the meaning of a preferential policy enacted in succession.
According to shenzhen science and information commission relevant personage introduces to the reporter, the city will be on Internet, new energy and biomedicine emerging industry development of billions of total super give money. "Soon, the first batch of biological medicine 35 support project will be approved.
Meanwhile, yunnan province 1025 "published" during vigorously develops the biological medicine, strive to achieve the billions scale.
Shanghai and Beijing are brewing issued his biological medicine "1025" planning. Shanghai is the overall objective of the end of 2012, to, make biological pharmacy economic volume 200 billion yuan. Support 100 annual output more than 2 billion yuan of innovative enterprise, make 100 sales more than 100 million yuan, a high content of technology fist product, And the Beijing strive to future three years the biomedicine industry scale from now of less than 400 million yuan increased to 100 billion yuan.
By 2010, yunda China biomedicine industry momentum of development such as emerging of the fire, quite have the fervour of power.
Flame is lit on October 18, the state council on speeding up the cultivating and developing strategic decision of emerging industries. Present will focus on energy conservation, environmental protection, cultivate and develop a new generation of information technology, biological seven new industry, until 2015, strategic emerging industry proportion of GDP to reach 8%.
Biological medicine is the next decade, the sunrise industry has been unquestionable. Chinese medicine transformation of scientific and technological achievements, director of the center RuiGuoZhong forecast, 2013 Chinese medicine market will become the world's third-biggest medicine market, By 2020, China biomedicine industry will reach the scale of 40000 million yuan, more than Japan and Europe to become the world's second largest pharmaceutical market. China in the global biomedicine industry growing status of ascension.
Multiple positive policy is coming out
Relevant expert points out, the 2010-2015 biomedicine industry revitalization planning "are being made in, before the end of the year is expected to come. Meanwhile, a batch of matching policy will around "1025" planning to come on stage, is expected to advance listed.
China biomedicine industry are entering policies benefiting period. According to introducing, "RuiGuoZhong from the macroscopic new medical policies overall implementation, base expanded version, new medicine GMP pharmaceutical production management (standard), biological medicine 863 plan, major new drugs oriented technology, to refining industry special the major infectious disease special", "drug registration management method", "new measures for the administration of medical devices, the Chinese medicine injection of new technology standards etc 689 policies, including throughout the biological medicine policy support, are all expected to come." year These good policy "not only more fierce, and concentrated, will reconstruct Chinese biological pharmacy chains."
China pharmaceutical industry confidence to Shanghai securities ZhongQian, director of the center, said biological medicine "1025" programming will put forward nine key projects, in which the first item is developing biological medicine to promote traditional Chinese medicine industry upgrading and give capital support. "To promote the pharmaceutical industry upgrading industries target, matching policy will soon out."
New GMP pharmaceutical industry and pharmaceutical standards () is now the biggest concern for one of the corresponding policy. China pharmaceutical enterprise management association, said YuMingDe drug quality guarantee system upgrade is the pharmaceutical industry is an important component of the overall upgrade. It is also decided to drug safety effective a foundation. "Revision GMP has passed, walking program, and also is expected to recent calafornia."
ZhongQian tells a reporter, new GMP have three years of transition, exceed the time limit not standard by the enterprise, namely were ordered to rectification or shut-down. "GMP pharmaceutical manufacturing company of the software requirements have boosted, this has been our medical enterprises the soft rib of."
Besides pharmaceutical standards, new drug product standards and the upgrade process. "In this five-year plan, the country will have a series of practical action to promote drug product standards improve. Including Chinese traditional medicine, tcmi, biochemical drugs, including apis and preparations injection impurities control and solvent residual, plus some new inspection items and methods. These are big change, also might release some new modern medicine product standards." YuMingDe said.
At the same time, to improve the innovation ability, the Shanghai securities reporter sole learns, and biological medicine "1025" planning also issued and major new drugs oriented 1025 "special" planning. For a significant innovation medicine development fund support scale will from the eleventh five-year plan period 6.6 billion expanded to 105 billion. The first 300 the winning project is expected to announce also years. Single drug development project support fund scale ranging from 100 to 10 million, technical development platform support from 1,000 to scale is 60 million dollars. These policies will be "the temptation" enterprise to increase development in addition, according to the Shanghai science and technology commission biological medicine place ZhengZhongMin revealed, deputy director of the legislative affairs office of the state council is in the present drug registration management method ", "new measures for the administration of medical devices, and hope it can discuss" scientific research institution between enterprises of the industrialization of the positioning."
High growth, high profit margin of the dual temptation
YuMingDe said the nation "1025" planning to determine the biological medicine, including genetic focusing on the development of drugs, protein drugs, single drug resistance, therapeutic cloning vaccine, small molecules chemical medicines, etc, these policies will actively promote the rapid development of China biological medicine, biological medicine industry exciting.
An adviser pharmaceutical industry GuoFan ritual to reporters researchers pointed out that China biomedicine industry in the future will remain rapid growth. "2009, China biological medicine industry total sales income reached 753 billion yuan, this development speed make it become the most rapidly growing pharmaceutical industry to one area. Meanwhile, biomedicine industry profit rate up to 70% high development speed and profitable growth also make biomedicine industry becomes emerging industry in one of the most remarkable object."
In the policy guidance and profitable, high rate of stimulating, a batch of traditional Chinese medicine companies will also send biological pharmaceutical companies change.
Specializes in production of traditional Chinese medicine intermediates for apis, main products listed pharmaceutical company manager told reporters, the company plans to use 5 to 10 years, thoroughly transform for biological pharmaceutical companies and has on research into huge funds. He revealed. "for refining comparing vaccine r&d investment projects 8,000 yuan, 2 years of RenYuan listed sales; anti-tumor bad factor of single resistance of total investment of the project 1 billion yuan.
Biological medicine investment projects for traditional medicine enterprise has brought tangible and sustainable profit growth. According to health yuan, deputy general manager of zhongshan introduces, at present by biological catalysis in henan jiaozuo way 7aca non-nanoparticlized antibiotics intermediates production has been very successful, the project has become the most important, and fastest growing source of their profits. "We use for soybean, corn fermentation to produce 7aca, free from pollution to the environment, current capacity is expanding."
In the United States nyse successful listing, China's largest high-tech medical equipment company - shenzhen Wallace rui biological medical electronics Co., relevant personage is put forward to the reporter, in the biological electronic medical devices field exists industrial supporting, technical standard loss, and foreign companies extrusion problems. He told reporters can foresee, 10 years biomedicine industry concentration more and more high, for large leading enterprises, government should provide better service, make public research and development platform, in order to improve their competitiveness.
For now, the government department all around has realised biomedicine industry for local economic development, and has the meaning of a preferential policy enacted in succession.
According to shenzhen science and information commission relevant personage introduces to the reporter, the city will be on Internet, new energy and biomedicine emerging industry development of billions of total super give money. "Soon, the first batch of biological medicine 35 support project will be approved.
No comments:
Post a Comment